- Home
- IKNA vs SST Comparison
IKNA vs SST Comparison
Compare IKNA & SST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKNA
- SST
- Stock Information
- Founded
- IKNA 2016
- SST 2013
- Country
- IKNA United States
- SST United States
- Employees
- IKNA N/A
- SST N/A
- Industry
- IKNA Biotechnology: Pharmaceutical Preparations
- SST Diversified Commercial Services
- Sector
- IKNA Health Care
- SST Consumer Discretionary
- Exchange
- IKNA Nasdaq
- SST Nasdaq
- Market Cap
- IKNA 64.7M
- SST N/A
- IPO Year
- IKNA 2021
- SST N/A
- Fundamental
- Price
- IKNA $1.32
- SST $0.37
- Analyst Decision
- IKNA Buy
- SST Strong Buy
- Analyst Count
- IKNA 2
- SST 1
- Target Price
- IKNA $3.00
- SST $5.00
- AVG Volume (30 Days)
- IKNA 84.4K
- SST 150.8K
- Earning Date
- IKNA 03-06-2025
- SST 03-10-2025
- Dividend Yield
- IKNA N/A
- SST N/A
- EPS Growth
- IKNA N/A
- SST N/A
- EPS
- IKNA N/A
- SST N/A
- Revenue
- IKNA N/A
- SST $343,925,000.00
- Revenue This Year
- IKNA N/A
- SST $8.34
- Revenue Next Year
- IKNA N/A
- SST N/A
- P/E Ratio
- IKNA N/A
- SST N/A
- Revenue Growth
- IKNA N/A
- SST N/A
- 52 Week Low
- IKNA $1.22
- SST $0.36
- 52 Week High
- IKNA $1.94
- SST $2.73
- Technical
- Relative Strength Index (RSI)
- IKNA 43.56
- SST 30.55
- Support Level
- IKNA $1.27
- SST $0.41
- Resistance Level
- IKNA $1.43
- SST $0.50
- Average True Range (ATR)
- IKNA 0.07
- SST 0.05
- MACD
- IKNA 0.00
- SST -0.00
- Stochastic Oscillator
- IKNA 37.21
- SST 7.43
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.